MDGL Madrigal Pharmaceuticals Inc

Price (delayed)

$74.55

Market cap

$1.28B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$15.08

Enterprise value

$1.27B

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum ...

Highlights
The equity has dropped by 69% year-on-year and by 43% since the previous quarter
The company's quick ratio has shrunk by 56% YoY and by 12% QoQ

Key stats

What are the main financial stats of MDGL
Market
Shares outstanding
17.1M
Market cap
$1.28B
Enterprise value
$1.27B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
15.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$255.12M
EBITDA
-$254.7M
Free cash flow
-$201.2M
Per share
EPS
-$15.08
Free cash flow per share
-$11.76
Book value per share
$4.88
Revenue per share
$0
TBVPS
$12.65
Balance sheet
Total assets
$216.39M
Total liabilities
$132.86M
Debt
$49.73M
Equity
$83.54M
Working capital
$130.54M
Liquidity
Debt to equity
0.6
Current ratio
2.55
Quick ratio
2.52
Net debt/EBITDA
0.01
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-100.6%
Return on equity
-155%
Return on invested capital
-175.5%
Return on capital employed
-192.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MDGL stock price

How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
-3.22%
1 week
1.08%
1 month
7.75%
1 year
-9.36%
YTD
-12.03%
QTD
4.15%

Financial performance

How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$255.62M
Net income
-$255.9M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 11% YoY and by 3.7% QoQ
MDGL's operating income is down by 10% YoY and by 3.5% QoQ

Growth

What is Madrigal Pharmaceuticals's growth rate over time

Valuation

What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
15.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 3.2% YoY and by 2.9% from the previous quarter
The stock's price to book (P/B) is 131% more than its 5-year quarterly average of 6.6 and 56% more than its last 4 quarters average of 9.8
The equity has dropped by 69% year-on-year and by 43% since the previous quarter

Efficiency

How efficient is Madrigal Pharmaceuticals business performance
The ROE has plunged by 78% YoY and by 33% from the previous quarter
Madrigal Pharmaceuticals's ROIC has plunged by 57% YoY and by 23% from the previous quarter
MDGL's return on assets is down by 37% year-on-year and by 15% since the previous quarter

Dividends

What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDGL.

Financial health

How did Madrigal Pharmaceuticals financials performed over time
Madrigal Pharmaceuticals's total assets is 63% more than its total liabilities
Madrigal Pharmaceuticals's total liabilities has soared by 132% YoY and by 73% from the previous quarter
The current ratio has dropped by 56% year-on-year and by 12% since the previous quarter
The debt is 40% smaller than the equity
The equity has dropped by 69% year-on-year and by 43% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.